Ipilimumab

IpilimumabIpilimumab

Ipilimumab

Stealth modeStealth Mode

Ipilimumab is a monoclonal antibody used in cancer immunotherapy, primarily targeting CTLA-4 to activate the immune system against cancer cells.

Website
DR 0Active
Rate
Advertise here

About

Ipilimumab, sold under the brand name Yervoy, is a fully human monoclonal antibody that targets CTLA-4, a protein receptor that downregulates the immune system. By blocking CTLA-4, ipilimumab activates T cells, thereby enhancing the body's immune response against cancer cells. It is approved for the treatment of various cancers, including melanoma, renal cell carcinoma, and colorectal cancer, often in combination with other therapies like nivolumab.
Frequently asked

What does Ipilimumab do?

Ipilimumab, sold under the brand name Yervoy, is a fully human monoclonal antibody that targets CTLA-4, a protein receptor that downregulates the immune system. By blocking CTLA-4, ipilimumab activates T cells, thereby enhancing the body's immune response against cancer cells. It is approved for the treatment of various cancers, including melanoma, renal cell carcinoma, and colorectal cancer, often in combination with other therapies like nivolumab.

What industry does Ipilimumab operate in?

Ipilimumab operates in Immunotherapy, Monoclonal Antibody, Oncology, Cancer Treatment, Biologic therapy.

New entrants in Oncology
Last 90 days
1
New entrants
0.3
Per month
0.1
Per week
Most recent
Cancerasia

An AI-powered platform for cancer patients and survivors in Asia to navigate care and understand their diagnosis.

Jul 5

An entrant is a company tagged Oncology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.

Comments

No comments yet. Be the first to share your take.